

# A phase II study of ARA 290 as therapeutic strategy in no-option critical limb ischemia patients.

Gepubliceerd: 10-01-2011 Laatst bijgewerkt: 18-08-2022

The objective of this proof-of-concept study is to test in no-option CLI patients whether ARA 290 (a) reduces limb pain, (b) reduces signs of local and systemic inflammation, and (c) promotes wound healing.

<b>Ethische beoordeling</b>	Positief advies
<b>Status</b>	Werving tijdelijk gestopt
<b>Type aandoening</b>	-
<b>Onderzoekstype</b>	Interventie onderzoek

## Samenvatting

### ID

NL-OMON28106

### Bron

NTR

### Aandoening

Critical limb ischemia

### Ondersteuning

**Primaire sponsor:** LUMC

**Overige ondersteuning:** fund = initiator = sponsor

### Onderzoeksproduct en/of interventie

### Uitkomstmaten

#### Primaire uitkomstmaten

1. Safety and tolerability parameters;<br>
2. General safety measurements;<br>
3. 12-lead ECG (only base line and visits on day 5 and 26);<br>

4. Hematology;<br>
5. Blood Biochemistry;<br>
6. Adverse Event monitoring;<br>
7. Pain Scores (VAS + Brief Pain Inventory);<br>
8. Allodynia and Hyperalgesia Testing;<br>
9. Autonomic nervous system measurement (only baseline and day 5);<br>
10. Analgesics use (diary);<br>
11. Wound healing (calibrated photos);<br>
12. Circulating inflammatory markers;<br>
13. Insulin sensitivity (fasting HOMA);<br>
14. Quality of life (RAND-36) (only base line and day 26).

## Toelichting onderzoek

### Achtergrond van het onderzoek

N/A

### DoeI van het onderzoek

The objective of this proof-of-concept study is to test in no-option CLI patients whether ARA 290 (a) reduces limb pain, (b) reduces signs of local and systemic inflammation, and (c) promotes wound healing.

### Onderzoeksopzet

Day 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26.

### Onderzoeksproduct en/of interventie

ARA 290 is an 11-amino acid, linear peptide that is being developed as a tissue protective peptide. ARA 290 is manufactured by standard F-moc solid phase peptide synthesis, purified by HPLC and ion-exchange chromatography, and stored as a lyophilized powder. ARA-290 will be administered 3 times a week for 4 weeks.

## Contactpersonen

### Publiek

Leiden University Medical Center

Dept. Vascular Surgery  
P.O.Box 9600  
Jan H.N. Lindeman  
Leiden 2300 RC  
The Netherlands  
+31 (0)71 5263968

## **Wetenschappelijk**

Leiden University Medical Center  
Dept. Vascular Surgery  
P.O.Box 9600  
Jan H.N. Lindeman  
Leiden 2300 RC  
The Netherlands  
+31 (0)71 5263968

## **Deelname eisen**

### **Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)**

1. Critical limb ischemia;
2. No option for conventional revascularization;
3. Written informed consent;
4. Expected life expectancy > 1 year.

### **Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)**

1. Poorly regulated diabetic disease (HbA1c >10%);
2. Clinically relevant abnormal history of physical and mental health other than conditions related to CLI, as determined by medical history taking (as judged by the investigator);
3. Clinically relevant abnormal laboratory results, ECG, vital signs, or physical findings other than conditions related to CLI (as judged by the investigator);
4. Subject has a history of severe allergies, or has had an anaphylactic reaction or significant

- intolerability to prescription or non-prescription drugs or food;
5. Participation in an investigational drug trial in the 3 months prior to administration of the initial dose of study drug or more than 4 times per year;
  6. Use of erythropoietin, systemic corticosteroids (e.g. prednisone etc.) and other immune modulatory drugs;
  7. Inability to follow the protocol and to comply with the follow up requirements;
  8. Any other condition that in the opinion of the investigator would complicate or compromise the study, or the well being of the subject.

## Onderzoeksopzet

### Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Parallel
Toewijzing:	N.v.t. / één studie arm
Blinding:	Open / niet geblindeerd
Controle:	N.v.t. / onbekend

### Deelname

Nederland	
Status:	Werving tijdelijk gestopt
(Verwachte) startdatum:	12-01-2011
Aantal proefpersonen:	12
Type:	Verwachte startdatum

## Ethische beoordeling

Positief advies	
Datum:	10-01-2011
Soort:	Eerste indiening

## Registraties

### Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

### Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

### In overige registers

Register	ID
NTR-new	NL2294
NTR-old	NTR2685
Ander register	METC LUMC / ABR : P10.85 / NL31947.058.10 ;
ISRCTN	ISRCTN wordt niet meer aangevraagd.

## Resultaten

### Samenvatting resultaten

N/A